02:42 PM EDT, 10/08/2024 (MT Newswires) -- Cassava Sciences ( SAVA ) has completed its phase 3 ReTHINK trial of simufilam for Alzheimer's disease, Chief Executive Rick Barry said in an open letter to the Cassava community on Tuesday.

All 804 patients with mild to moderate Alzheimer's disease have completed dosing across the sites in the US, Puerto Rico, Canada and Australia. Top-line results are expected before the end of 2024, Barry said.

Cassava shares were up nearly 2% in recent trading.

Price: 25.91, Change: +0.50, Percent Change: +1.97